Genenta Science Obtains $21.9 Million Financing to Expand Pipeline

MT Newswires Live03-19

Genenta Science (GNTA) said Wednesday it has obtained a 20 million euro ($21.9 million) financing via the issuance of a mandatory convertible bond to ENEA Tech and Biomedical, or ETB, to advance temferon in metastatic renal cell cancer.

ETB is a private foundation supervised by Italy's Ministry of Enterprises, the company said.

Genenta Chief Executive Pierluigi Paracchi said the bond's conversion to equity is set for March 2028, followed by a lock-up period of two years.

The company said a phase 1/2a trial in metastatic renal cell carcinoma has started enrolling patients.

Genenta also said the February data cutoff from a phase 1/2a glioblastoma multiforme trial showed "an increase in the percentage of patients surviving at two years," rising to 29% from 25% in October.

Price: 3.71, Change: -0.08, Percent Change: -2.11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520913268?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-19 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520913268","market":"sg","top_or_hot":-1,"title":"Genenta Science Obtains $21.9 Million Financing to Expand Pipeline","media":"MT Newswires Live","content":"<html><body><p> Genenta Science (GNTA) said Wednesday it has obtained a 20 million euro ($21.9 million) financing via the issuance of a mandatory convertible bond to ENEA Tech and Biomedical, or ETB, to advance temferon in metastatic renal cell cancer.</p><p>ETB is a private foundation supervised by Italy's Ministry of Enterprises, the company said.</p><p>Genenta Chief Executive Pierluigi Paracchi said the bond's conversion to equity is set for March 2028, followed by a lock-up period of two years.</p><p>The company said a phase 1/2a trial in metastatic renal cell carcinoma has started enrolling patients.</p><p>Genenta also said the February data cutoff from a phase 1/2a glioblastoma multiforme trial showed \"an increase in the percentage of patients surviving at two years,\" rising to 29% from 25% in October.</p><p>Price: 3.71, Change: -0.08, Percent Change: -2.11</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genenta Science Obtains $21.9 Million Financing to Expand Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenenta Science Obtains $21.9 Million Financing to Expand Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-19 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Genenta Science (GNTA) said Wednesday it has obtained a 20 million euro ($21.9 million) financing via the issuance of a mandatory convertible bond to ENEA Tech and Biomedical, or ETB, to advance temferon in metastatic renal cell cancer.</p><p>ETB is a private foundation supervised by Italy's Ministry of Enterprises, the company said.</p><p>Genenta Chief Executive Pierluigi Paracchi said the bond's conversion to equity is set for March 2028, followed by a lock-up period of two years.</p><p>The company said a phase 1/2a trial in metastatic renal cell carcinoma has started enrolling patients.</p><p>Genenta also said the February data cutoff from a phase 1/2a glioblastoma multiforme trial showed \"an increase in the percentage of patients surviving at two years,\" rising to 29% from 25% in October.</p><p>Price: 3.71, Change: -0.08, Percent Change: -2.11</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GNTA","symbol_name":"Genenta Science S.p.A.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520913268","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520913268","pubTimestamp":1742395072,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genenta Science  said Wednesday it has obtained a 20 million euro  financing via the issuance of a mandatory convertible bond to ENEA Tech and Biomedical, or ETB, to advance temferon in metastatic renal cell cancer.ETB is a private foundation supervised by Italy's Ministry of Enterprises, the company said.Genenta Chief Executive Pierluigi Paracchi said the bond's conversion to equity is set for March 2028, followed by a lock-up period of two years.The company said a phase 1/2a trial in metastatic renal cell carcinoma has started enrolling patients.Genenta also said the February data cutoff from a phase 1/2a glioblastoma multiforme trial showed \"an increase in the percentage of patients surviving at two years,\" rising to 29% from 25% in October.Price: 3.71, Change: -0.08, Percent Change: -2.11","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GNTA":"Genenta Science S.p.A.","BK4139":"生物科技"},"translate_title":"Genenta Science获得2190万美元融资以扩大管线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNTA":0.9},"content_text":"Genenta Science (GNTA) said Wednesday it has obtained a 20 million euro ($21.9 million) financing via the issuance of a mandatory convertible bond to ENEA Tech and Biomedical, or ETB, to advance temferon in metastatic renal cell cancer.ETB is a private foundation supervised by Italy's Ministry of Enterprises, the company said.Genenta Chief Executive Pierluigi Paracchi said the bond's conversion to equity is set for March 2028, followed by a lock-up period of two years.The company said a phase 1/2a trial in metastatic renal cell carcinoma has started enrolling patients.Genenta also said the February data cutoff from a phase 1/2a glioblastoma multiforme trial showed \"an increase in the percentage of patients surviving at two years,\" rising to 29% from 25% in October.Price: 3.71, Change: -0.08, Percent Change: -2.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520913268"}